| | | | |

Physicians and patients weigh in on latest poorly designed study that raises the question, “Why?”, and, “Who is driving this spin?”

Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease


“Persister research needs to account for morphological variability of Lyme

The patient population studied was already a group that had shown persistence of disease. These would be “treatment failures” and more difficult cases. Even in this difficult population every group who received 2 weeks of IV ceftriaxone made an average 5 point improvement, and this 5 point improvement from their baseline essentially continued for a year after the conclusion of treatment, giving a new improved baseline. Ceftriaxone acts on the cell wall, whereas doxycycline and clarithromycin have intracellular activity…..”

Read full text


Stay safe in the outdoors

Your support can change lives

Get our news and updates by email

Similar Posts

One Comment

Comments are closed.